Multiple Sclerosis

News Multiple Sclerosis

• Bayer achieves strong gains in sales and earnings

  The Bayer Group started off 2010 with strong sales and earnings growth. “Bayer is well on track – and we plan to grow again this year,” said Werner Wenning, Chairman of the Board of Management, when the first-quarter report was published on Thursday. MaterialScience posted a clear recovery in an inc more

• IMS Forecasts Global Pharmaceutical Market Growth of 5-8% Annually through 2014

  IMS Health reported that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion (ex manufacturer prices) over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading produc more

• Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing

  Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was announced in more

Publications Multiple Sclerosis

• Prognostic Risk Estimates of Patients with Multiple Sclerosis and Their Physicians: Comparison to an Online Analytical Risk Counseling Tool

  by Christoph Heesen, Wolfgang Gaissmaier, Franziska Nguyen, Jan-Patrick Stellmann, Jürgen Kasper, Sascha Köpke, Christian Lederer, Anneke Neuhaus, Martin Daumer Background Prognostic counseling in multiple sclerosis (MS) is difficult because of the high variability of disease progression. Simulta more

• Minocycline reduces remyelination by suppressing ciliary neurotrophic factor expression after cuprizone‐induced demyelination

  Abstract Remyelination is disrupted in demyelinating diseases such as multiple sclerosis, but the underlying pathogenetic mechanisms are unclear. In this study, we employed the murine cuprizone model of demyelination, in which remyelination occurs after removal of the toxin from the diet, to exa more

• Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors

  RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glauco more

Websites Multiple Sclerosis